This is not the most recent version of the article. View current version (18 APR 2015)

Intervention Protocol

TNF-alpha inhibitors for ankylosing spondylitis

  1. Jane Zochling1,*,
  2. Lara Maxwell2,
  3. Jil Beardmore2,
  4. Annelies Boonen3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 20 JUL 2005

DOI: 10.1002/14651858.CD005468


How to Cite

Zochling J, Maxwell L, Beardmore J, Boonen A. TNF-alpha inhibitors for ankylosing spondylitis (Protocol). Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005468. DOI: 10.1002/14651858.CD005468.

Author Information

  1. 1

    Menzies Research Institute, Hobart, Tasmania, Australia

  2. 2

    University of Ottawa, Institute of Population Health, Ottawa, Ontario, Canada

  3. 3

    Caphri Research Institute, Department of Rheumatology, 6202 AZ Maastricht, Netherlands

*Jane Zochling, Menzies Research Institute, Private Bag 23, Hobart, Tasmania, 7001, Australia. jane.zochling@utas.edu.au. jzochling@bigpond.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JUL 2005

SEARCH

This is not the most recent version of the article. View current version (18 APR 2015)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To summarize the efficacy and safety of infliximab, etanercept and adalimumab (TNF-alpha inhibitors) for the short-term and long-term treatment of ankylosing spondylitis.